Karyopharm Therapeutics (NASDAQ:KPTI) Reaches New 1-Year Low on Analyst Downgrade

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) reached a new 52-week low during trading on Monday after Robert W. Baird lowered their price target on the stock from $35.00 to $30.00. Robert W. Baird currently has an outperform rating on the stock. Karyopharm Therapeutics traded as low as $8.94 and last traded at $9.00, with a volume of 45258 shares changing hands. The stock had previously closed at $9.34.

Other equities analysts have also issued reports about the stock. Royal Bank of Canada decreased their price objective on shares of Karyopharm Therapeutics from $24.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday. SVB Leerink lowered their price target on Karyopharm Therapeutics from $22.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday. Barclays cut their price objective on Karyopharm Therapeutics from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, February 12th. Finally, Zacks Investment Research cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $27.00.

In other news, insider Sharon Shacham sold 4,000 shares of the business’s stock in a transaction dated Thursday, March 18th. The stock was sold at an average price of $12.39, for a total transaction of $49,560.00. Following the completion of the transaction, the insider now directly owns 920,152 shares of the company’s stock, valued at $11,400,683.28. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 14,681 shares of company stock valued at $207,959 in the last quarter. Company insiders own 13.26% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Oder Investment Management LLC purchased a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $26,000. Penserra Capital Management LLC grew its stake in shares of Karyopharm Therapeutics by 169.1% during the fourth quarter. Penserra Capital Management LLC now owns 1,690 shares of the company’s stock worth $26,000 after purchasing an additional 1,062 shares in the last quarter. Lindbrook Capital LLC increased its holdings in Karyopharm Therapeutics by 5,145.9% in the fourth quarter. Lindbrook Capital LLC now owns 3,200 shares of the company’s stock valued at $50,000 after buying an additional 3,139 shares during the last quarter. Captrust Financial Advisors lifted its holdings in Karyopharm Therapeutics by 600.0% during the 4th quarter. Captrust Financial Advisors now owns 3,500 shares of the company’s stock worth $54,000 after buying an additional 3,000 shares during the last quarter. Finally, Victory Capital Management Inc. acquired a new position in shares of Karyopharm Therapeutics during the 1st quarter worth about $120,000. Institutional investors own 88.56% of the company’s stock.

The firm has a 50-day moving average price of $10.35 and a two-hundred day moving average price of $13.98. The firm has a market cap of $636.52 million, a price-to-earnings ratio of -2.92 and a beta of 0.93. The company has a debt-to-equity ratio of 1.38, a quick ratio of 5.39 and a current ratio of 5.42.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Sunday, May 2nd. The company reported ($0.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.06). Karyopharm Therapeutics had a negative net margin of 221.23% and a negative return on equity of 187.66%. Research analysts anticipate that Karyopharm Therapeutics Inc. will post -2.72 earnings per share for the current year.

Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)

Karyopharm Therapeutics Inc, a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1.

Recommended Story: Bar Chart

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.